Clinical Trials Logo

Tobacco Use Disorder clinical trials

View clinical trials related to Tobacco Use Disorder.

Filter by:

NCT ID: NCT03507127 Not yet recruiting - Tobacco Dependence Clinical Trials

Targeted Pharmacological and Behavioral Treatments for Smoking in Schizophrenia Study 1

Start date: April 2018
Phase: Phase 2
Study type: Interventional

Schizophrenia is associated with high rates of cigarette smoking and associated morbidity and mortality. In this study, smokers with schizophrenia will complete a baseline session and then randomized to varenicline (VAR) or placebo (PLA). After 1 week on medication, participants will complete a cigarette rating task session. Participants will then undergo a 72-hr abstinence period in which they will come to the laboratory twice per day and receive high-value cash reinforcement contingent upon meeting a strict breath CO abstinence criterion. At each visit, they will rate withdrawal symptoms, mood and craving. At the end of the abstinence period, they will repeat the cigarette rating task. Participants will return to the lab to provide a CO sample 24 hours later, and will text the lab with videos of their CO samples for one week. Date and time of smoking relapse will be measured from these samples.

NCT ID: NCT03506867 Not yet recruiting - Nicotine Dependence Clinical Trials

A Healthy People Initiative: Building the Socio-Economic Capital of Low Income Population At-Risk for HIV and Hepatitis-C

Start date: June 1, 2018
Phase: N/A
Study type: Interventional

"Health is a state of complete physical, mental and social well-being, and not merely the absence of disease or infirmity" (World Health Organization, 1948). Diseases such as HIV/AIDS and Hepatitis-C (HCV) thrive in conditions of poverty and marginalization. Research on the quality of life of people living with HIV/AIDS reveals that unemployed individuals report more depression, anxiety, social isolation, and low self-esteem than employed individuals. Moreover, unemployment is a key factor in the contemplation of suicide among people with HIV/AIDS. Alternatively, employment among people living with HIV/AIDS is a strong indicator of improved quality of life. A finding the study investigators confirmed in a research study (PROMPT) supporting 80 members of Ottawa's low income homeless (or at-risk for homelessness) People Who Use Drugs reduce (and in some cases quit) smoking. PROMPT participants repeatedly stated that boredom and a lack of meaningful social connections and employment were major hindrances in their reduction and overall recovery from smoking and drug use. With these PROMPT findings, the investigators propose a Community-Based Participatory Action project that builds the social capital of 80 participants that identify as members of Ottawa and Toronto's low income People Who Use drugs living with or are at-risk for HIV/AIDS/HCV. The proposed multi-site project will include life-skills training, counseling, health services access (testing and treatment), and education on HIV/AIDS/HCV. Most importantly the project will include a poverty reduction intervention that connects participants with education opportunities, short-term work and volunteer opportunities. The education, work and volunteer opportunities' will be made possible with the support of local business owners and networks that support the study's poverty reduction and community building elements. The aim of project will be to demonstrate the feasibility and cost of a holistic healthcare that encourages a state of complete physical, mental, and social well-being.

NCT ID: NCT03497299 Not yet recruiting - Schizophrenia Clinical Trials

Combining rTMS With Varenicline to Prevent Smoking Lapse in Schizophrenia

Start date: July 1, 2018
Phase: Phase 2
Study type: Interventional

Tobacco smokers with schizophrenia are known to be resistant smokers, with high rates of smoking and inability to quit in the long-term, often related to smoking relapse. This may relate to problems with frontal lobe function associated with schizophrenia, which make these patients have great difficulty in dealing with smoking withdrawal, urges and cravings. The current study will develop a combination approach that takes advantage of brain stimulation of the frontal lobes (repetitive transcranial magnetic stimulation (rTMS), in combination with the anti-smoking drug varenicline, to prevent smoking lapse using a well-established human laboratory method. Results from this study may have important implications for developing novel treatment approaches for smokers with schizophrenia.

NCT ID: NCT03496116 Not yet recruiting - Nicotine Dependence Clinical Trials

The Influence of Electronic (ECIG) Heater Resistance on ECIG Acute Effects

Start date: May 2018
Phase: N/A
Study type: Interventional

The purpose of this study is to measure the individual and combined influence of electronic cigarette (ECIG) heating element resistance and liquid nicotine concentration on ECIG acute effects. Thirty-two experienced ECIG users will complete four independent laboratory sessions that will differ by heater resistance (0.5 ohm or 1.5 ohm) and liquid nicotine concentration (3 or 8 mg/ml). Other factors such as voltage, liquid solvent ratio, and liquid flavor will be held constant. Plasma nicotine concentration, subjective effects, and puffing behavior will be recorded for each condition.

NCT ID: NCT03496077 Not yet recruiting - Clinical trials for Tobacco Use Disorder

Addictive Potential of LCCs in Dual Users

Start date: April 2018
Phase: N/A
Study type: Interventional

This study is about whether or not little cigars and cigarillos cause or maintain addiction, and if flavors, such as fruit, make them more addictive. The purpose of this study is to understand the addiction potential of little cigars and cigarillos compared to cigarettes in young adults who smoke both products. This study will also look at the differences between men and women. In the rest of this form, little cigars or cigarillos will be referred to as LCCs.

NCT ID: NCT03492463 Not yet recruiting - Clinical trials for Nicotine Dependence, Cigarettes

The Role of Nicotine Dose and Route of Delivery in Affecting Adoption of E-cigarettes and Reducing Exposure to Toxic Combustion Products

ENDS-Switch
Start date: July 1, 2018
Phase: Phase 2
Study type: Interventional

This study plans to investigate whether using electronic cigarettes (e-cigarettes) or skin patches containing nicotine affects switching from smoking conventional combustible (burning) cigarettes.

NCT ID: NCT03473483 Not yet recruiting - Nicotine Dependence Clinical Trials

Cigarette Harm Reduction With Scheduled Electronic Cigarette Use

NIDA-SREC
Start date: June 1, 2018
Phase: N/A
Study type: Interventional

This is an observational, crossover study that will be examine use behaviors, chemical exposures, and biological effects of SREC compared to TC use in subjects confined to a research ward setting.

NCT ID: NCT03471767 Recruiting - Smoking Cessation Clinical Trials

AXS-05 Phase II Trial on Smoking Behavior

Start date: March 25, 2018
Phase: Phase 2
Study type: Interventional

This research study is designed with the purpose of evaluating a new drug, combination Dextromethorphan-Bupropion (AXS-05), for its effects on smoking behavior.

NCT ID: NCT03463837 Recruiting - Tobacco Use Clinical Trials

Identify Biomarkers of Tobacco Exposure and Nicotine Uptake From JUUL 5% in Adult Smokers

Diamond
Start date: March 6, 2018
Phase: N/A
Study type: Interventional

The JUUL 5% Electronic Nicotine Delivery System (ENDS) is being studied as an alternative to combustible cigarette use. This study aims to find out how much nicotine is in the blood and urine of healthy adult subjects after using three JUUL 5% ENDS compared to smoking usual brands of combustible cigarettes and stopping smoking.

NCT ID: NCT03450941 Not yet recruiting - Smoking Cessation Clinical Trials

AXS-05 Phase II Trial on Smoking Behavior

Start date: March 15, 2018
Phase: Phase 2
Study type: Interventional

This research study is designed with the purpose of evaluating a new drug, combination Dextromethorphan-Bupropion (AXS-05), for its effects on smoking behavior.